20.41
0.44 (2.20%)
| Penutupan Terdahulu | 19.97 |
| Buka | 20.39 |
| Jumlah Dagangan | 159,166 |
| Purata Dagangan (3B) | 842,834 |
| Modal Pasaran | 2,257,218,560 |
| Harga / Jualan (P/S) | 4.75 |
| Harga / Buku (P/B) | 2.85 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -60.26% |
| Margin Operasi (TTM) | -52.88% |
| EPS Cair (TTM) | -2.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.72% |
| Nisbah Semasa (MRQ) | 3.26 |
| Aliran Tunai Operasi (OCF TTM) | -186.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -184.48 M |
| Pulangan Atas Aset (ROA TTM) | -15.50% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.05% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zai Lab Limited | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.38 |
|
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.47% |
| % Dimiliki oleh Institusi | 52.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| C Worldwide Group Holding A/S | 30 Sep 2025 | 510,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |